Pasithea Therapeutics Corp. (KTTA): Price and Financial Metrics
GET POWR RATINGS... FREE!
KTTA POWR Grades
- Sentiment is the dimension where KTTA ranks best; there it ranks ahead of 92.78% of US stocks.
- The strongest trend for KTTA is in Growth, which has been heading down over the past 70 days.
- KTTA ranks lowest in Value; there it ranks in the 0th percentile.
KTTA Stock Summary
- KTTA's went public 1.37 years ago, making it older than just 2.35% of listed US stocks we're tracking.
- With a price/sales ratio of 78.36, PASITHEA THERAPEUTICS CORP has a higher such ratio than 97.13% of stocks in our set.
- As for revenue growth, note that KTTA's revenue has grown 1,632.23% over the past 12 months; that beats the revenue growth of 99.3% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to PASITHEA THERAPEUTICS CORP, a group of peers worth examining would be NISN, AQB, DGLY, CYAN, and INGN.
- To dig deeper into the stock's financial statements, go to KTTA's page on browse-edgar?action=getcompany&CIK=0001841330.
KTTA Valuation Summary
- In comparison to the median Healthcare stock, KTTA's price/earnings ratio is 110.57% lower, now standing at -2.4.
- KTTA's price/earnings ratio has moved up 965.9 over the prior 16 months.
Below are key valuation metrics over time for KTTA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| KTTA | 2023-01-20 | 76.6 | 0.4 | -2.4 | 2.6 |
| KTTA | 2023-01-19 | 77.4 | 0.4 | -2.5 | 2.6 |
| KTTA | 2023-01-18 | 80.8 | 0.5 | -2.6 | 2.5 |
| KTTA | 2023-01-17 | 80.8 | 0.5 | -2.6 | 2.5 |
| KTTA | 2023-01-13 | 78.2 | 0.4 | -2.5 | 2.6 |
| KTTA | 2023-01-12 | 73.6 | 0.4 | -2.3 | 2.7 |
KTTA Stock Price Chart Interactive Chart >
KTTA Price/Volume Stats
| Current price | $0.70 | 52-week high | $1.54 |
| Prev. close | $0.66 | 52-week low | $0.54 |
| Day low | $0.65 | Volume | 552,913 |
| Day high | $0.73 | Avg. volume | 123,070 |
| 50-day MA | $0.79 | Dividend yield | N/A |
| 200-day MA | $1.03 | Market Cap | 20.56M |
Pasithea Therapeutics Corp. (KTTA) Company Bio
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. The company also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. Pasithea Therapeutics Corp. was incorporated in 2020 and is based in Miami Beach, Florida.
Latest KTTA News From Around the Web
Below are the latest news stories about PASITHEA THERAPEUTICS CORP that investors may wish to consider to help them evaluate KTTA as an investment opportunity.
Majority of Stockholders Support Pasithea Directors at Special MeetingMIAMI BEACH, Fla., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders, today announced the final results of the Special Meeting of Stockholders (“Special Meeting”) held on December 9, 2022. According to the certified voting results provided by the Independent Inspector of Elections, a significant ma |
Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac GroupMIAMI BEACH, Fla., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders, today announced that it has reached a comprehensive Settlement and Cooperation Agreement (“the Agreement”) with Concord IP2 Ltd., Elderhill Corporation, Leonite Capital LLC, Leonite Fund I, LP, Camac Partners, LLC, Camac Capital, |
Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea TherapeuticsNEW YORK & TORONTO, December 07, 2022--Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the "Investor Group" or "we"), who are collectively the largest external stockholder of Pasithea Therapeutics Corp. (Nasdaq: KTTA) ("Pasithea" or the "Company"), today issued the below statement recommending stockholders vote on the WHITE proxy card to remove the Company’s Board of Directors (the "Board") at the upcoming Special |
Pasithea Therapeutics to Present at Annual Meeting of the Antibody Society ConferencePAS-003 is a first in class monoclonal antibody targeting Alpha 5 Beta 1 integrin as a treatment for amyotrophic lateral sclerosis (ALS) and other neuroinflammatory-driven CNS diseasesMIAMI BEACH, Fla., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of innovative treatments for Central Nervous System (CNS) disorders, today announced that Lawrence Steinman, Pasit |
Pasithea Therapeutics Postpones Special Meeting until December 9, 2022 at 9:00 AM Eastern TimeMIAMI BEACH, Fla., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (“CNS”) disorders, today announced that it has postponed its Special Stockholder Meeting (the “Special Meeting”) originally scheduled for November 29, 2022 to allow additional time for stockholder voting proxies (the “Notice”). The Special Meetin |
KTTA Price Returns
| 1-mo | 9.09% |
| 3-mo | -34.58% |
| 6-mo | -43.09% |
| 1-year | -45.74% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 9.09% |
| 2022 | -63.75% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...